COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
NextPoint Therapeutics develops precision immuno-oncology therapies targeting the HHLA2 (B7‑H7) pathway, advancing clinical-stage programs NPX267 and NPX887 and biomarker-driven tumor-targeting modalities for PD‑1/PD‑L1 non-responders.
